Pulmonary sarcoidosis

4 trials 2 recruiting MedDRA PT
4 Registered trials
2 Recruiting
3 Unique sponsors
2 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 4
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Phase III: 2 Phase II: 2

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase III

2 trials
  • aTYR Pharma Inc. Commercial
    EFZOFITIMOD
    2023-506039-13-00 5 countries 2023 n=101 Orphan
    Ended
  • Assistance Publique Hopitaux De Paris Academic
    IMP not specified
    2024-516101-23-00 1 country 2024 n=200
    Recruiting

Phase II

2 trials
  • Molecure S.A. Commercial
    5-(4-((2S,5S)-5-(4-CHLOROBENZYL)-2-METHYLMORPHOLINO)PIPERIDIN-1-YL)-1H- 1,2,4-TRIAZOL-3-AMINE
    2023-506642-23-00 6 countries n=72
    Not authorised
  • Molecure S.A. Commercial
    5-(4-((2S,5S)-5-(4-CHLOROBENZYL)-2-METHYLMORPHOLINO)PIPERIDIN-1-YL)-1H- 1,2,4-TRIAZOL-3-AMINE
    2023-506642-23-01 6 countries 2024 n=65
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Molecure S.A. Commercial 2 Phase II 1
aTYR Pharma Inc. Commercial 1 Phase III 0
Assistance Publique Hopitaux De Paris Academic 1 Phase III 1
New trials by year
2023
1
2024
2
← All indication landscapes